Description

cis-(Platinum-Dichloro(Doxorubicin)(tert-Butylamine)) is a specialized platinum-based coordination complex designed for advanced pharmaceutical research and development. This compound is engineered to combine the chemotherapeutic activity of platinum with the anthracycline framework of doxorubicin, representing a significant area of study in targeted oncology therapeutics. It is a critical material for researchers and developers in the fields of anticancer drug discovery, medicinal chemistry, and novel drug delivery systems, particularly for investigating synergistic mechanisms and reducing systemic toxicity.

Application

• Anticancer Drug Discovery: Serves as a key intermediate or lead compound in the research and development of novel platinum-anthracycline hybrid chemotherapeutic agents.
• Mechanistic Studies: Used in biochemical and pharmacological research to investigate the synergistic effects, cellular uptake, and DNA-binding mechanisms of combined platinum/doxorubicin therapies.
• Medicinal Chemistry & SAR: Provides a versatile scaffold for structure-activity relationship (SAR) studies to optimize efficacy and pharmacokinetic profiles.
• Targeted Delivery System Development: Employed in the design and evaluation of ligand-directed or nanoparticle-based delivery platforms aimed at improving tumor selectivity.
• Preclinical Research: Utilized in in vitro and in vivo models to assess antitumor activity, toxicity, and therapeutic windows of new drug candidates.
• Reference Standard: Acts as a high-purity analytical standard for quality control and method development in pharmaceutical analysis.

Basic Information

Item	Detail
Product Name	cis-(Platinum-Dichloro(Doxorubicin)(tert-Butylamine))
CAS No.	107283-77-2
Molecular Formula	C₃₃H₄₀Cl₂N₃O₁₂Pt
Molecular Weight	948.68 g/mol
Synonyms	cis-Dichloro(doxorubicin)(tert-butylamine)platinum(II); Platinum-doxorubicin tert-butylamine complex; Doxorubicin platinum complex; cis-Platinum doxorubicin adduct; cis-[PtCl₂(doxorubicin)(t-BuNH₂)]; (SP-4-2)-Dichloro[14-hydroxy-7-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-4,6,11-trihydroxy-9,10-dihydro-7H-tetracene-5,12-dionato(2-)-κO⁵,κO¹²](tert-butylamine)platinum; Platinum(II) doxorubicin tert-butylamine dichloride
EINECS	Contact for details

Quality Control

Our cis-(Platinum-Dichloro(Doxorubicin)(tert-Butylamine)) is manufactured under controlled conditions to ensure the highest standards of purity and consistency required for pharmaceutical research. All batches undergo rigorous analytical characterization, including HPLC for purity and identity confirmation. A comprehensive Certificate of Analysis (COA) detailing batch-specific results is provided with every shipment to support your regulatory and quality assurance needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and should be handled under anhydrous conditions to maintain stability.

Specification

Item	Specification
Appearance	Orange to red-orange solid
Identification (HPLC)	Conforms to reference
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 95.0%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.